Osteosarcoma Normal Tissues HumanDog Companion Animal Cancer Models  Large outbred Animals  Strong Genetic similarities to Humans  Naturally Occurring.

Slides:



Advertisements
Similar presentations
Small Molecule PD and Imaging – Models and Assay Development DCTD Phase 0 Primer, September 5, 2007 Ralph E Parchment, PhD SAIC-Frederick, Inc., NCI-Frederick,
Advertisements

Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.
Amy K. LeBlanc, DVM Diplomate ACVIM (Oncology)
Clinical Implementation of Genomic Cancer Medicine
Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.
Pelvic Breakout Group. Purpose of meeting What is current status of radiation oncology technologies today. Where should we invest research resources to.
Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI
Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine
What are clinical trials? Phases of Clinical Trials Clinical trials of new medicines are done in phases: Phase I Phase II Phase III.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Clinical Trials The Way We Make Progress Against Disease.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
ICARE Member Reports ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial.
Introducing Apceden™.
The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2.
Bernard A Fox, PhD Immediate Past President and Chair, Executive Council Society for Immunotherapy of Cancer (SITC) Defining the Critical Hurdles in Cancer.
High Expression of Ezrin, a Determinant of Metastatic Behavior, in Ewing’s Sarcoma Kartik Krishnan, Gaurav Khanna, Stephen Hewitt, Chand Khanna, and Lee.
1 Safety Pharmacology for Oncology Pharmaceuticals at CDER John K. Leighton Associate Director for Pharmacology CDER/OND/OODP.
Multimodality Therapy Nic Denko Radiation Biology 2011.
SARC Developmental Therapeutics Committee Update Chand Khanna Open Science: Biology to Therapy” SARC Developmental Therapeutics Committee Update Chand.
Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Clinical Pharmacy Part 2
Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.
The Future of Cancer and Treatments Abby Bridge AP Biology Period 1.
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.
Antibody and prodrug therapy of cancer
CTOS IS TEN YEARS OLD SARC IS TWO YEARS OLD Happy Birthday, CTOS, SARC.
ABT-526 and ABT-510, Antiangiogenic Thrombospondin-1 Peptides, Are Active in Dogs With Naturally Occurring Canine Cancers Including Soft Tissue Sarcomas.
Metals in Medicine Consortium Sydney Cancer Centre.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
Developing medicines for the future and why it is challenging Angela Milne.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Letters of Intent (LOIs) Through the NCI’s Cancer Therapy Evaluation Program (CTEP) Dr. Patricia M. LoRusso, D.O. Karmanos Cancer Institute Wayne State.
Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.
Dinutuximab (ch14.18) for children with high-risk neuroblastoma
FDA’s Public Workshop: Innovative Systems for Delivery of Drugs and Biologics: Scientific, Clinical, and Regulatory Challenges Paul Goldfarb, MD, FACS.
Progress of the SNM Clinical Trials Network Michael Graham, PhD, MD Clinical Trials Network Co-Chair SNM President 1.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
Robert H. Wiltrout Director, CCR Director’s Address.
Rationale for Developing New Drugs 25% of children with cancer will not survive 5 years25% of children with cancer will not survive 5 years The acute toxicity.
C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
Nanoparticles for Medical and Surgical Tumor Therapy Departments of Radiology, Oncology and Biomedical Engineering Emory University School of Medicine.
Patients access to investigational drugs Steinar Aamdal Dept. of Clinical Cancer Research Oslo University Hospital.
 Define Survivorship  Demonstrate understanding of the history of cancer survivorship  State the requirements of the Commission on Cancer of the American.
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
Recent Studies Funded by the Progressive MS Alliance Tim Coetzee, PhD ACTRIMS 2016.
NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.
1 Trends in drug development programs in the era of Personalized Medicine Gunnar Saeter, M.D., Ph.D. Head, Institute for Cancer Research Oslo University.
Animal models of breast and prostate cancer “Advances in targeting cancer pathways” by Cinbo delegates MEDITERRANEAN SCHOOL OF ONCOLOGY 08 April 2016,
RAS Initiative at the Federally Funded Research and Development Center at Frederick Presented By: Sara S. Hook October 1, 2015.
Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.
종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.
Accelerating Precision Medicine for Advanced Cancer Patients
Broadening Eligibility Criteria to Make Clinical Trials More Representative Joint Recommendations of the American Society of Clinical Oncology and Friends.
From Bench to Clinical Applications: Money Talks
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Protocol Summary National Wilms Tumor Study Group (NWTS)
Rational for the 5R Philosophy
Cancer is a Challenge Cancer is common in humans – a public health problem ~1 of every 3 women will develop cancer ~1 of every 2 men will develop cancer.
Volume 21, Issue 9, Pages (September 2014)
role of comparative oncology in translational research
Pillars of WARF Therapeutics: Invest - Develop - Partner
The 3rd Stat4Onc Annual Symposium
Presentation transcript:

Osteosarcoma Normal Tissues HumanDog

Companion Animal Cancer Models  Large outbred Animals  Strong Genetic similarities to Humans  Naturally Occurring cancers  Immune competant and syngeneic  Relevant Tumor Histology/Genetics  Relevant Response Profiles to Conventional Chemotherapy  Tumor Heterogeneity  Metastasis Biology  Recurrence/Resistance Cancer IN Companion Animals  65 Million Companion Animals in the US  4 million pet dogs diagnosed with cancer each year  Pet owners seek advanced care for their pets Comparative Oncology TO PROVIDE OPPORTUNITIES TO INCLUDE NATURALLY OCCURRING CANCER MODELS IN THE STUDY OF CANCER BIOLOGY AND THERAPY

The CCR - Comparative Oncology Program Develop essential reagent kit for the study of comparative models in translational and biology-based research; Develop multicenter collaborative network with extramural comparative oncology programs. Within this network design, implement and manage pre-clinical trials involving pet animals that will evaluate novel therapeutic strategies for cancer; Increase the awareness of the appropriate use of naturally occurring cancer models within the cancer research community;

Resources and Reagents: opportunities for Layered Translation Human Serum Canine Serum #1 Canine Serum #2 Canine Serum #3

Comparative Oncology Trials Consortium (COTC)

Draft Trial Overview -2-3 Page Summary - Internal Review Trial Overview Board -CCR/CTEP/DTP Members - Focus on value of dog trial to development path COTC Consortium Members -Review Trial Overviews Solicit Ad Hoc Community Reviews -Individuals/Groups likely to be involved in clinical development Re-draft Approval Package Decision Package for CCR Directors Solicit Ad Hoc Community to Review Full Protocol (JDC) -Individuals/Groups likely to be involved in clinical development and/or data management COTC Consortium Members -Review Full Protocol Commence Trial Collaboration Initiated -Pharma -NCI CCR-COP -Academia Re-draft Trial Review Process: Effort to ensure integration

Integration of a Comparative Approach Activity Toxicity Pharmacokinetics Pharmacodynamics Dose Regimen Schedule Biomarkers Responding Histologies Combination therapies Small Animal Preclinical Phase III Human Clinical Trials Tumor-Bearing Dog Studies Phase II Human Clinical Trials Phase I Human Clinical Trials Tumor-Bearing Dog Studies Non-Human Primate Beagle Dog New Cancer Drug

Large Pharma Merck  Status: CDA in place, meeting to discuss collaborations has been scheduled for early January Astrazeneca  Status: Meeting is planned for mid-November to discuss a trial in pet dogs. Small Pharma/Biotech Genzyme  Status: CRADA meeting and presentation completed. Locus Pharmaceuticals  Status: CDA has been completed and a Trial Overview is being drafted.

Academia/Biotech SemaCo  Status: CDA IN PLACE, in vitro evaluation underway (T Olgios in canine OSA cell lines) Colando Pharmaceuticals  Status: Currently validating their anti-RRM2 antibody in canine normal and tumor tissues by Western and Immunohistochemical analysis. Center for Cancer Research  Radiation Oncology (Jim Mitchel) Tempol  Evaluation of intravenous Tempol in pet dogs receiving fractionated radiation therapy in dogs with head and neck cancer  Status - Trial overview in second review  Surgery Branch (Steve Libutti) Phage Delivery of TNF-   Evaluation of RGD Targeted Delivery of Phage Expressing TNF-  To Tumor Bearing Dogs  Status - Trial approved for initiation

News Nature Medicine 11, 1018 (2005) Published online: 28 September 2005; | doi: /nm a Cancer researchers usher in dog days of medicine George S Mack Columbia, South Carolina After thousands of years of friendship, man and dog will soon be working together to advance drug discovery. As part of a new comparative-oncology program at the US National Cancer Institute, researchers are set to begin drug trials in dogs that aim to bridge the gap between preclinical drug studies and effects of the same drug in people. Two multicenter trials, set to begin in early 2006, will evaluate new therapeutic approaches for cancer in dogs, says program chief Chand Khanna, a veterinary oncologist at the institute's Center for Cancer Research. "It turns out that many cancers, such as lymphoma, melanoma and osteosarcoma, are well represented in pet dogs," Khanna says. "The dogs will help us prioritize the agents that go into human clinical trials and help make those trials more efficient." Wall Street Journal July 7, 2005 Nature Medicine October 2005 The Good News…We have arrived. Now we must deliver

Acknowledgments Comparative Oncology Program CCR, National Cancer Institute Melissa Paoloni Christina Mazcko Katherine Hansen Tumor and Metastasis Biology Section, PEDIATRIC ONCOLOGY BRANCH CCR, National Cancer Institute Ling Ren Arnulfo Mendoza Jessica Cassavaugh Rachel Blackwood Sung-Hyeok Hong Lauren Shapiro Ben Bruce Rachel Newman Gaurav Khanna

Acknowledgments Molecular Oncology Section Pediatric Oncology Branch CCR, National Cancer Institute Xiaolin Wan Choh Yeung Lee Helman Tissue Array Research Project (TARP), CCR Stephen Hewitt Kimberly Parker Biomedical Proteomics Program, CCR LiRoung Yu Ming Zhou Tim Veenstra Cornell University Anthony Bretscher Columbia University Charles Powell Alain Borczuk University of Michigan Evan Keller University of Umea Goran Landberg State University of Ohio Mark Berryman LCMB, CCR, National Cancer Institute Yanlin Yu Glenn Merlino Cancer Genetics Branch, NHGRI Kristin Baird Paul Meltzer Oncogenomics Section, POB, NCI Javed Khan Carcinogenesis/Prevention, CCR Nancy Colburn